Markers of Atherosclerosis: Part 1-Serological Markers

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F19%3A00070966" target="_blank" >RIV/00159816:_____/19:00070966 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/19:00108495

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1443950618319164?via%3Dihub#" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1443950618319164?via%3Dihub#</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.hlc.2018.06.1057" target="_blank" >10.1016/j.hlc.2018.06.1057</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Markers of Atherosclerosis: Part 1-Serological Markers

Popis výsledku v původním jazyce

Atherosclerosis is a major contributor to morbidity and mortality worldwide. With therapeutic consequences in mind, several risk scores are being used to differentiate individuals with low, intermediate or high cardiovascular (CV) event risk. The most appropriate management of intermediate risk individuals is still not known, therefore, novel biomarkers are being sought to help re-stratify them as low or high risk. This narrative review is presented in two parts. Here, in Part 1, we summarise current knowledge on serum (serological) biomarkers of atherosclerosis. Among novel biomarkers, high sensitivity C-reactive protein (hsCRP) has emerged as the most promising in chronic situations, others need further clinical studies. However, it seems that a combination of serum biomarkers offers more to risk stratification than either biomarker alone. In Part 2, we address genetic and imaging markers of atherosclerosis, as well as other developments relevant to risk prediction.

Název v anglickém jazyce

Markers of Atherosclerosis: Part 1-Serological Markers

Popis výsledku anglicky

Atherosclerosis is a major contributor to morbidity and mortality worldwide. With therapeutic consequences in mind, several risk scores are being used to differentiate individuals with low, intermediate or high cardiovascular (CV) event risk. The most appropriate management of intermediate risk individuals is still not known, therefore, novel biomarkers are being sought to help re-stratify them as low or high risk. This narrative review is presented in two parts. Here, in Part 1, we summarise current knowledge on serum (serological) biomarkers of atherosclerosis. Among novel biomarkers, high sensitivity C-reactive protein (hsCRP) has emerged as the most promising in chronic situations, others need further clinical studies. However, it seems that a combination of serum biomarkers offers more to risk stratification than either biomarker alone. In Part 2, we address genetic and imaging markers of atherosclerosis, as well as other developments relevant to risk prediction.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

<a href="/cs/project/NV17-29701A" target="_blank" >NV17-29701A: Ischémií modifikovaný albumin a cirkulující mikroRNA jako nové technologie k monitorování tkáňové ischémie po cévních rekonstrukcích na břišní aortě</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Heart Lung and Circulation

ISSN

1443-9506

e-ISSN

—

Svazek periodika

28

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

667-677

Kód UT WoS článku

000462780100007

EID výsledku v databázi Scopus

—